The pharmaceutical market is a strange beast. In Canada, patients can access generic versions of Ozempic, the blockbuster diabetes drug, at a fraction of the price paid by Americans. Yet south of the border, where free-market principles reign, the same drug remains under patent and costs a small fortune. The UK’s NHS, often criticised for its bureaucratic inefficiencies, finds itself in an awkward position: it pays less than the US but has no generic alternative. This divergence highlights the tangled interplay of patent law, government negotiation, and market incentives.
Let us start with the numbers. In the US, a month’s supply of Ozempic can set you back nearly $1,000 without insurance. In Canada, the generic version, produced by a handful of manufacturers, costs around $200. The reason is simple: Canadian law allows for compulsory licensing and early generic entry under certain conditions, whereas the US operates under a strict patent regime that rewards innovation but stifles competition. The result is a classic case of rent-seeking. Big Pharma argues that high US prices fund research and development, but the reality is more nuanced. The US government, unlike its Canadian or British counterparts, is barred from negotiating drug prices directly with manufacturers. This is a political choice not an economic necessity.
The NHS, meanwhile, has a different headache. It negotiates bulk discounts with drug companies, securing lower prices than the US but higher than some European neighbours. However, the NHS has no generic Ozempic because the patent in the UK runs until 2032. The Canadian generic is produced under a compulsory licence granted because the patent holder failed to manufacture the drug domestically in sufficient quantities. The UK lacks such provisions. This is a policy gap that costs the taxpayer millions. The question is whether the UK should follow Canada’s lead and allow generic competition earlier, or risk compromising the long-term incentive for innovation.
The market, as ever, will find its equilibrium. Capital flight from high-cost environments is a real risk. If the US continues to allow exorbitant prices, more patients will turn to black markets or cross-border purchases. The UK, with its state-run healthcare system, must balance fiscal responsibility with access. The Treasury is watching the gilts yield curve nervously. Any move to accelerate generic entry would cause pharmaceutical shares to wobble, but the long-term gain to public finances could be substantial.
Critics of the Canadian model argue that it discourages investment. But the data suggests otherwise. Canada has a thriving pharmaceutical R&D sector, albeit smaller than the US. The key is maintaining a stable regulatory environment. The US has become a hostage to its own patent system, with drug companies spending more on marketing and stock buybacks than on research. The market efficiency argument collapses when perverse incentives dominate.
For the UK, the lesson is clear. The NHS model, while far from perfect, at least recognises that healthcare is not a commodity. But it must be more aggressive in tackling patent abuse. The government could borrow a page from Canada’s book and introduce compulsory licensing for essential drugs when the patent holder is failing to meet demand. This would not be a revolution it would be a sensible adjustment of the rules.
The bottom line is this: the US has no generic Ozempic because its system prioritises corporate profits over public health. Canada has it because its laws put patients first, within limits. The UK sits in the middle, but with a creeping sense that its model, while efficient in many ways, lacks the teeth to challenge pharmaceutical monopolies. The market will eventually correct, but the question is whether it will be through policy reform or through a messy, disruptive crash. For now, investors should watch the dividend cuts at big pharma and the rising yields on long-dated gilts. Something has to give.
